Xtant Medical Enters Into Distribution Agreement With Curasan for Matriform

Xtant Medical Holdings Inc., a developer of regenerative medicine products and medical devices, has entered into a distribution agreement with curasan Inc., adding a premium line of synthetic scaffolds to its biologics portfolio. 
 
Matriform, Xtant’s brand of the curasan synthetic product portfolio for orthopedic applications, consists of a composition of pure phase Beta-Tricalcium Phosphate (β-TCP) and porcine collagen, and interconnected porosity with a variety of micro, meso, and macro pores. Distribution of Matriform will mark Xtant’s entrance into the U.S. orthopedic bone graft substitute market, the largest market globally with an annual market size of over $800 million.
 
“We are excited to be enhancing our biologic portfolio offering with a line of synthetic scaffolds, which will make us a comprehensive biologic supplier for our customers and their patients,” said Carl O’Connell, CEO of Xtant Medical. “Our team has been very strategic in finding a partner with a product that meets our expectations for superior handling and clinical efficacy with proven mechanisms of action.”

Matriform will be available in two formulations, and in various volumes for a multitude of orthopedic applications. The flexible strips are high density with high elasticity, making them easily adaptable to bony defects when hydrated. The moldable version is a low density bioceramic that becomes malleable when hydrated. The two formulations received U.S. Food and Drug Administration 510(k) clearance for orthopedic applications in December of 2016, and has been a synthetic of choice in Europe for a variety of orthopedic procedures for over 20 years.
 
“It’s an important milestone for us to partner with such a forward-thinking company as Xtant Medical and expand our distribution footprint within North America. Adding additional private label distributors within the US and globally alongside our direct sales teams provide great opportunities for curasan and our distributor partners. Xtant has a great reputation for providing innovative and relevant products to orthopedic surgeons and we are pleased to expand our relationship further with Xtant,” said Michael Schlenk, CEO of curasan AG. 
 
Xtant Medical Holdings Inc. develops, manufactures, and markets regenerative medicine products and medical devices for domestic and international markets. Xtant products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, and foot and ankle surgeries.
 
curasan develops, manufactures, and markets biomaterials and medical devices in the field of bone and tissue regeneration, wound healing and osteoarthritis therapy. curasan is specialized primarily on biomimetic bone grafting materials for dental, oral/maxillofacial, orthopedic and spinal applications, i.e., materials mimicking biological structures. Numerous patents and a broad record of scientific publications demonstrate the clinical success of the products and the highly innovative strength of curasan. Dental and orthopaedic clinicians worldwide benefit from the broad range of the premium quality and easy to use portfolio offered by curasan. The company maintains its own high-tech facilities for research, development and manufacturing of biomaterials in Frankfurt, Germany. In addition to its headquarters, the company has a subsidiary, curasan Inc., in the Research Triangle Park area, near Raleigh, N.C. curasan´s products are cleared by the U.S. Food and Drug Administration and many other international authorities and available in almost 50 countries worldwide.